US · ATYR
aTyr Pharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- atyrpharma.com
Price · as of 2024-12-31
$0.83
Market cap 94.05M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.78 | +2,753.03% |
| Intrinsic Value(DCF) | $1.36 | +63.17% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $20.53 | +2,363.59% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $71.40 | ||||
| 2016 | $50.40 | ||||
| 2017 | $42.00 | ||||
| 2018 | $6.30 | ||||
| 2019 | $3.83 | ||||
| 2020 | $4.92 | $351.51 | $2.32 | $0.00 | $0.00 |
| 2021 | $5.24 | $22.70 | |||
| 2022 | $1.94 | $1.64 | $0.00 | ||
| 2023 | $1.59 | $31.62 | $0.55 | $0.00 | $79.21 |
| 2024 | $3.40 | $23.78 | $0.00 | $0.00 | $20.53 |
AI valuation
Our deep-learning model estimates aTyr Pharma, Inc.'s (ATYR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.78
- Current price
- $0.83
- AI upside
- +2,753.03%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.36
+63.17% upside
Graham-Dodd
—
— upside
Graham Formula
$20.53
+2,363.59% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATYR | aTyr Pharma, Inc. | $0.83 | 94.05M | +2,753% | +63% | — | +2,364% | -3.94 | 3.61 | 1074.42 | -2.92 | — | 3.61 | 100.00% | -28899.57% | -27243.83% | -79.69% | -723.88% | -58.88% | 0.19 | — | 5.48 | 4.93 | -0.03 | -851.00% | -3343.00% | 8481.00% | -27.40% | -4.62 | -737.41% | 0.00% | 0.00% | 0.00% | -2.85 | -2.80 | 824.03 | -3.56 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| ALXO | ALX Oncology Holdings Inc… | $2.11 | 114.42M | — | — | — | — | -0.41 | 0.49 | — | 0.42 | — | 0.49 | 0.00% | — | — | -88.91% | -1054.84% | -69.10% | 0.15 | -82.40 | 7.26 | 6.95 | 0.00 | -3102.00% | — | -705.00% | -221.24% | -6.59 | -905.96% | 0.00% | 0.00% | 0.00% | 0.39 | 0.45 | — | -7.15 |
| CAMP | CAMP4 Therapeutics Corpor… | $4.49 | 95.37M | — | -59% | — | — | -1.58 | 1.29 | 125.35 | -0.51 | -0.81 | 1.29 | 100.00% | -8142.33% | -7943.40% | 719.97% | 75.53% | -57.27% | 0.14 | — | 6.92 | 6.68 | 1.08 | 19556.00% | — | 807.00% | -56.29% | -4.75 | 65.45% | 0.00% | 0.00% | 0.00% | -0.50 | -0.57 | 40.39 | -1.91 |
| DTIL | Precision BioSciences, In… | $4.20 | 55.67M | +1,686% | -46% | +221% | +1,082% | 4.94 | 0.63 | 0.52 | -1.54 | — | 0.63 | 100.00% | -38.08% | 10.43% | 19.05% | 78.77% | 4.84% | 0.53 | -14.68 | 6.34 | 5.88 | -4.13 | -10652.00% | 4098.00% | -3206.00% | -165.83% | -3.90 | 176.73% | 0.00% | 0.00% | 0.00% | 0.80 | 0.36 | -0.30 | -4.11 |
| HYFT | MindWalk Holdings Corp. | $1.13 | 52.76M | +1,308% | +315% | — | — | -2.28 | 2.92 | 2.84 | -2.48 | — | 4.82 | 47.31% | -50.47% | -123.30% | -105.08% | -30.71% | -57.90% | 0.57 | -1237.63 | 2.08 | 1.72 | -0.09 | -1262.00% | -203.00% | 2775.00% | -10.44% | -0.71 | -20.45% | 0.00% | 0.00% | 10.84% | -5.85 | -9.96 | 2.95 | -2.17 |
| MGX | Metagenomi, Inc. Common S… | $1.52 | 57.07M | +1,047% | +86% | — | — | -0.99 | 0.33 | 1.48 | 1.50 | -6.69 | 0.33 | 100.00% | -170.00% | -149.26% | -34.69% | -676.50% | -22.64% | 0.19 | — | 6.91 | 6.69 | -0.22 | 1484.00% | 1684.00% | 1083.00% | -144.84% | -2.92 | -913.98% | 0.00% | 0.00% | 0.00% | 1.41 | 1.11 | -2.39 | -0.37 |
| QNCX | Quince Therapeutics, Inc. | $0.13 | 7M | — | — | — | — | -1.15 | 2.17 | — | -1.09 | -2.05 | -2.18 | 0.00% | — | — | -98.63% | -409.00% | -38.57% | 0.49 | — | 6.05 | 5.72 | -0.24 | 5595.00% | — | 7430.00% | -49.23% | -4.38 | -229.62% | 0.00% | 0.00% | 0.00% | -0.69 | -1.22 | — | -5.41 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| UNCY | Unicycive Therapeutics, I… | $6.93 | 148.94M | +172% | — | — | — | -1.03 | 5.08 | — | -0.34 | -0.30 | 5.08 | 0.00% | — | — | -2028.11% | 209.66% | -160.18% | 0.10 | -452.35 | 1.28 | 1.08 | 0.70 | 33750.00% | -10000.00% | 5658.00% | -75.83% | -1.18 | 187.01% | 2.90% | -3.00% | 46.52% | -0.39 | -0.43 | — | -6.63 |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- CEO
- Sanjay S. Shukla
- Employees
- 56
- Beta
- 0.58
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.36 ÷ $0.83) − 1 = +63.17% (DCF, example).